Wednesday, 4 February 2015

GcMAF Factory Raided

News from the UK's medical regulator, the MHRA, following a raid on the Cambridgeshire lab which was manufacturing GcMAF. This is a blood product that is sold over the internet as a cure for cancer, autism and a host of other conditions. While there is one bona fide early trial on GcMAF on-going in Israel, the product is being sold from a variety of websites as an actual cure. There is no evidence that it is a cure - and the Anticancer Fund of Belgium has been working hard examining the evidence that exists. To date a number of the papers that the people selling GcMAF have been using as 'evidence' have been retracted (withdrawn from the journals in which they were published). There is a good summary of the evidence at the Anticancer Fund website.

In this latest news from the MHRA, concern was raised about the safety of the product:

The blood plasma starting material being used to make this drug stated “Not to be administered to humans or used in any drug products”. It was concluded that the production site does not meet Good Manufacturing Practice (GMP) standards and there are concerns over the sterility of the medicine being produced and the equipment being used. There are concerns that the product may be contaminated.

The conclusion from the MHRA is stark:

These products may pose a significant risk to people’s health. Not only were the manufacturing conditions unacceptable but the originating material was not suitable for human use. GcMAF products labelled as ‘First Immune’ are not licensed medicines and have not been tested for quality, safety or effectiveness. People should not start treatment with these specific products. It is important that patients currently taking these products seek their doctor’s advice as soon as possible. People should continue taking prescribed medicines and follow the advice of their doctor.

Update: The BBC have reported that the government of Guernsey, where many of the companies selling GcMAF are based, has banned the importation of GcMAF. 

No comments:

Post a comment